WO2003080118A3 - Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique - Google Patents

Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique Download PDF

Info

Publication number
WO2003080118A3
WO2003080118A3 PCT/US2003/008206 US0308206W WO03080118A3 WO 2003080118 A3 WO2003080118 A3 WO 2003080118A3 US 0308206 W US0308206 W US 0308206W WO 03080118 A3 WO03080118 A3 WO 03080118A3
Authority
WO
WIPO (PCT)
Prior art keywords
aldosterone receptor
fibric acid
combination
acid derivative
receptor antagonist
Prior art date
Application number
PCT/US2003/008206
Other languages
English (en)
Other versions
WO2003080118A2 (fr
Inventor
Bradley T Keller
Ellen G Mcmahon
Original Assignee
Pharmacia Corp
Bradley T Keller
Ellen G Mcmahon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Bradley T Keller, Ellen G Mcmahon filed Critical Pharmacia Corp
Priority to IL16389803A priority Critical patent/IL163898A0/xx
Priority to JP2003577943A priority patent/JP2005523302A/ja
Priority to KR10-2004-7014574A priority patent/KR20040107482A/ko
Priority to BR0308494-9A priority patent/BR0308494A/pt
Priority to MXPA04009032A priority patent/MXPA04009032A/es
Priority to EP03719400A priority patent/EP1485132A2/fr
Priority to AU2003223287A priority patent/AU2003223287A1/en
Priority to CA002479722A priority patent/CA2479722A1/fr
Publication of WO2003080118A2 publication Critical patent/WO2003080118A2/fr
Publication of WO2003080118A3 publication Critical patent/WO2003080118A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)

Abstract

L'invention concerne des méthodes et des combinaisons destinées au traitement et/ou à la prophylaxie d'état pathologique chez un patient, les méthodes consistant à administrer un ou plusieurs antagonistes de récepteur d'aldostérone et un ou plusieurs dérivés d'acide fibrique, les combinaisons comprenant un ou plusieurs antagonistes de récepteur d'aldostérone et un ou plusieurs dérivés d'acide fibrique.
PCT/US2003/008206 2002-03-18 2003-03-18 Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique WO2003080118A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL16389803A IL163898A0 (en) 2002-03-18 2003-03-18 Combination of an aldosterone receptor antagonist and a fibric acid derivative
JP2003577943A JP2005523302A (ja) 2002-03-18 2003-03-18 アルドステロン受容体アンタゴニストおよびフィブリン酸誘導体の併用
KR10-2004-7014574A KR20040107482A (ko) 2002-03-18 2003-03-18 알도스테론 수용체 길항물질 및 피브르산 유도체의 혼합물
BR0308494-9A BR0308494A (pt) 2002-03-18 2003-03-18 Combinação de um antagonista de receptores de aldosterona e de um derivado do ácido fìbrico
MXPA04009032A MXPA04009032A (es) 2002-03-18 2003-03-18 Combinacion de un antagonista del receptor de aldosterona y un derivado del acido fibrico.
EP03719400A EP1485132A2 (fr) 2002-03-18 2003-03-18 Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique
AU2003223287A AU2003223287A1 (en) 2002-03-18 2003-03-18 Combination of an aldosterone receptor antagonist and a fibric acid derivative
CA002479722A CA2479722A1 (fr) 2002-03-18 2003-03-18 Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36524202P 2002-03-18 2002-03-18
US60/365,242 2002-03-18

Publications (2)

Publication Number Publication Date
WO2003080118A2 WO2003080118A2 (fr) 2003-10-02
WO2003080118A3 true WO2003080118A3 (fr) 2004-01-15

Family

ID=28454632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008206 WO2003080118A2 (fr) 2002-03-18 2003-03-18 Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique

Country Status (12)

Country Link
EP (1) EP1485132A2 (fr)
JP (1) JP2005523302A (fr)
KR (1) KR20040107482A (fr)
CN (1) CN1642573A (fr)
AU (1) AU2003223287A1 (fr)
BR (1) BR0308494A (fr)
CA (1) CA2479722A1 (fr)
IL (1) IL163898A0 (fr)
MX (1) MXPA04009032A (fr)
PL (1) PL372588A1 (fr)
WO (1) WO2003080118A2 (fr)
ZA (1) ZA200407462B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101286743B1 (ko) * 2011-02-18 2013-07-15 충남대학교산학협력단 페노피브레이트를 함유하는 패혈증 예방용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038725A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinaisons utilisees dans le cadre de troubles cardio-vasculaires
WO2002000653A2 (fr) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Modulateurs cycliques condenses de la fonction du recepteur hormonal nucleaire
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038725A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinaisons utilisees dans le cadre de troubles cardio-vasculaires
WO2002000653A2 (fr) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Modulateurs cycliques condenses de la fonction du recepteur hormonal nucleaire
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
EP1312379A1 (fr) * 2000-08-25 2003-05-21 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene

Also Published As

Publication number Publication date
CA2479722A1 (fr) 2003-10-02
WO2003080118A2 (fr) 2003-10-02
CN1642573A (zh) 2005-07-20
IL163898A0 (en) 2005-12-18
KR20040107482A (ko) 2004-12-20
BR0308494A (pt) 2005-05-03
EP1485132A2 (fr) 2004-12-15
PL372588A1 (en) 2005-07-25
AU2003223287A1 (en) 2003-10-08
ZA200407462B (en) 2006-07-26
JP2005523302A (ja) 2005-08-04
MXPA04009032A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
ZA200408670B (en) Trizole derivatives as tachykinin receptor antagonists.
MXPA04000586A (es) Combinacion de un atagonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa.
WO2007027734A3 (fr) Heterocycles d'azote pontes et bicycliques
WO2001066534A3 (fr) Antagonistes du recepteur d'histamine-3 diamino cycliques et bicycliques
IL165871A0 (en) Substituted quinoline CCR5 receptor antagonists
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
WO2007073432A3 (fr) Derives de la piperidine et procedes d’utilisation
WO2001076574A3 (fr) Combinaison de composes organiques
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
EP1734966A4 (fr) Utilisation de derives de piperazinylpiperidine comme antagonistes de recepteurs de chimiokines
AU2003255501A1 (en) Cxcr4 receptor antagonists
WO2002017895A3 (fr) Utilisation d'un antagoniste du recepteur d'aldosterone pour ameliorer la fonction cognitive
HK1079708A1 (zh) 可用作毒蕈碱性受體拮抗劑的3，6-二取代氮雜二環[3．1．10]己烷衍生物
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
WO2005009362A3 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
WO2005060947A3 (fr) Ligands agonistes et antagonistes du recepteur de la nociceptine
IL164016A0 (en) Azetidine derivatives as ccr-3 receptor antagonists
WO2002011732A8 (fr) Nouveaux derives de pyrrolidine bicycliques et tricycliques comme antagonistes de gnrh
WO2005037224A3 (fr) Antagonistes du recepteur acetylcholine muscarinique
AP2005003196A0 (en) Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
AU2003300904A1 (en) Antagonists for human prolactin
WO2006016192A3 (fr) Polytherapie pour le traitement de la schizophrenie
AU2003256793A1 (en) Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003233127A1 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501395

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003223287

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 163898

Country of ref document: IL

Ref document number: 535049

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003719400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/07462

Country of ref document: ZA

Ref document number: 200407462

Country of ref document: ZA

Ref document number: 1020047014574

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009032

Country of ref document: MX

Ref document number: 372588

Country of ref document: PL

Ref document number: 2479722

Country of ref document: CA

Ref document number: 2003806300X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003577943

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003719400

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047014574

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020047014574

Country of ref document: KR